with MSB® sodium butyrate

The best resarched butyrate on the market

The composition of the products is based on evidence from clinical trials and the practical experience of physicians and dietitians.

Comprehensive solution
for the gut health and beyond

The original and patented MSB® technology provides gradual and even release of butyrate in the duodenum, jejunum, ileum, and colon, distinguishing it from other products.

Patent-protected technology of gradual release

Energast® safety and efficacy
proven by:

• 7 clinical studies involving more than 3.300 patients*,

• 10 years of clinical research in IBS, IBD, diverticular disease, SIBO, diabetes type 2

Safety
& efficacy

Comprehensive support for intestinal disorders

Differences in release profiles of various butyrate-containing products mean that preparations
may exert distinctly different effects on intestinal function.

MSB® technology ensures gradual and even release of butyrate in the duodenum, jejunum, ileum, and colon,
clearly distinguishing it from other butyrate formulations.

*https://food-forum.pl/artykul/suplementacja-kwasem-
maslowym-forma-podania-i-implikacje-kliniczne

Why butyrate release profile is so important?

MSB® : Targeted, Sustained Butyrate Delivery for Clinical Impact

Gradual and sustained release of sodium butyrate is essential for achieving therapeutic efficacy,
as butyrate is rapidly and efficiently utilized by intestinal epithelial cells at the site of release.

Intestinal disorders and diseases affect both the small and large intestine.

The high efficacy and safety of products containing MSB® butyrate have been confirmed in 6 clinical trials involving over 3.300 patients.

Due to significant differences in release profiles and sodium butyrate dosages, the clinical findings apply exclusively to MSB® and cannot be extrapolated to other butyrate formulations.

Clinical effects
of MSB®
supplementation

Energast®Line is designed to compensate the butyric acid deficiency in the intestines by delivering butyrate in a proprietary MSB® form.

• Energast® is available in the form of capsules and sachets from 150 mg to 750 mg dosage in one portion of the product.

• Available dosages were clinically tested in various disorders.

•  

• Clean label:
  products are vegan, free of gluten, lactose and other sugars, fibre, artificial dyes or flavours. Sachets contain natural fruit flavor (cranberry).

You think butyrate?
Choose Energast®

Want to know more how Energast works?

Download general MSB® brochure
 

Download brochure on MSB® butyrate release profile
 

To receive brochure with summary of clinical study results
with MSB® butyrate - contact us

Contact us to start developing

*The total number of patients participating in studies using Energast® was calculated on the basis of the following publications:

1. Krokowicz L. et al. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study. Two-centre, parallel, double blinded, randomized, placebo-controlled, per-protocol clinical: Int J Colorectal Dis Dec 2013

2. Tarnowski W et al.: Outcome of treatment with butyric acid in irritable bowel syndrome – preliminary report. Gastroenterologia Praktyczna 1/2011.

3. Krokowicz L., Kaczmarek BF., Krokowicz P. et al.: Sodium butyrate and short chain fatty acids in prevention of travellers’ diarrhoea: a randomized prospective study. Travel Medicine and Infectious Disease. 2014 Mar-Apr;12(2):183-8.

4. Banasiewicz T. et al.: Quality of life and clinical symptoms in patients with irritable bowel syndrome receiving complementary treatment with protected sodium butyrate. Gastroenterologia Praktyczna 5/2011.

5. Banasiewicz T. et al.: Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Disease 2012; The Association of Coloproctology of Great Britain and Ireland. 15,204-209

6. Lewandowski K. et al.: The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Przegląd Gastroenterologiczny2022;17(1):28-34.

7. Panufnik P. et al.: Effect of Butyrate on GI signs, SIBO, and Diabetes Control—Randomized, Placebo-Controlled Study in Patients with Type 2 Diabetes. Diabetes 2024;73(Supplement_1):610-P. 10.2337/db24-610-P

8. Goldiș A. et al.: Clinical Efficacy of Sodium Butyrate in Managing Pediatric Inflammatory BowelDisease. Life (Basel). 2025 May 31;15(6):902. doi: 10.3390/life15060902. PMID: 40566555; PMCID: PMC12193763.

The Bioton S.A. Group has for years pursued a policy of manufacturing and introducing to the Polish and international markets effective and safe medicinal products, foods for special medical purposes, dietary supplements, and medical devices that meet global standards. Thanks to innovative production technologies and implemented quality assurance and control procedures, all products are manufactured under conditions that meet the quality requirements appropriate to each product category, including international Good Manufacturing Practice (GMP) requirements, as evidenced by continuously maintained quality certifications. Product quality and safety play a key role in the adopted quality policy, carried out by a highly specialized and competent team of experts. A high standard is ensured at every stage—from development, through manufacturing and storage, to distribution. At the same time, through ongoing monitoring and continuous improvement of quality initiatives, the implemented Quality System is maintained, ensuring adherence to the highest quality standards.

info@biolek.com.pl